Molecular Targeting in Oncology

Introduction

Contents

Contributors

I General Strategies for Molecular Targeting in Oncology

The Cell Cycle

mTOR

Ras/Raf/MEK Inhibitors

17-AAG

The Cancer Epigenome

II Molecular Targeting for Specific Disease Sites

Molecular Targeting in Upper Gastrointestinal Malignancies

Molecular Targeting of Colorectal Cancer

Molecular Targeting in Hepatocellular Carcinoma

Molecularly Targeted Therapy in Pancreatic Cancer

Untargeted Use of Targeted Therapy

Renal Cell Carcinoma

Targeted Therapies for Prostate Cancer

Molecular Targets in Ovarian Cancer and Endometrial Cancer

Targeted Therapy For Breast Cancer

Melanoma

III Classes of Drugs for Molecular Targeting in Oncology

Antibody Therapy of Cancer

Nucleic Acid Therapies for Cancer Treatment

Engineering Oncolytic Measles Viruses for Targeted Cancer Therapy

Vaccines as Targeted Cancer Therapy

Cytokine-Based Therapy for Cancer

Cyclooxygenase-2 as a Target for Cancer Prevention and Treatment

IV Specific Drugs for Molecular Targeting in Oncology

Imatinib Mesylate (Gleevec and the Emergence of Chemotherapeutic Drug- Resistant Mutations

Development of a Targeted Treatment for Cancer

VEGF Inhibition for Cancer Therapy

Somatostatin Analogue Therapy

V Challenges in Molecular Targeting in Oncology

Patient Selection for Rational Development of Novel Anticancer Agents

Clinical Trial Design with Targeted Agents

How to Define Treatment Success or Failure if Tumors Do Not Shrink

Molecular Imaging in Oncology

Combinations of Molecular- Targeted Therapies

Preclinical Development of Molecularly Targeted Agents in Oncology

Index